Pirenzepine in non-ulcer dyspepsia. A double-blind, placebo controlled trial.
Fifty patients (with non-ulcer dyspepsia) were admitted to a double-blind, placebo-controlled trial to study the effects of pirenzepine (100 mg/daily) on non-ulcer dyspepsia. Ten patients did not complete the trial. After 4 weeks of treatment, statistically significant improvement (P less than 0.001) was observed endoscopically in the pirenzepine group. The relief of dyspepsia was significantly greater in the pirenzepine-treated group. The tolerability of pirenzepine was good.
D000328:Adult; D001570:Benzodiazepinones / Q000009:adverse effects / Q000627:therapeutic use*; D002986:Clinical Trials as Topic; D004311:Double-Blind Method; D004415:Dyspepsia / Q000188:drug therapy*; D004724:Endoscopy; D005260:Female; D005753:Gastric Mucosa / Q000473:pathology; D006801:Humans; D007413:Intestinal Mucosa / Q000473:pathology; D008297:Male; D010276:Parasympatholytics / Q000009:adverse effects / Q000627:therapeutic use*; D010890:Pirenzepine; D010919:Placebos
D001570:Benzodiazepinones; D010276:Parasympatholytics; D010919:Placebos; D010890:Pirenzepine